John Trojanowski, 75, a Giant in the Field of Neuropathology
In a career that spanned more than 40 years, Trojanowski broadened and deepened the field's understanding of the molecular pathology of neurodegenerative diseases.
ALL NEWS
6512 RESULTS
Sort By:
- Most Recent
- Most Commented
CMS Plans to Limit Aduhelm Coverage to Clinical Trials
The decision will curtail access until efficacy is shown. Many Alzheimer’s researchers call it a reasonable compromise, others question how it will work in practice.
Sylvain Lesné, Who Found Aβ*56, Accused of Image Manipulation
Other scientists found indications of potentially doctored western blots in multiple papers, including several on Aβ*56. Investigations are underway at journals, NIH, UMinnesota.
Peter Davies, Beloved Giant of Alzheimer’s Disease Research, Dies at 72
In a career spanning four decades, Davies spearheaded the cholinergic hypothesis, unlocked secrets of tau, and readily shared antibodies in the field.
Aducanumab Approved to Treat Alzheimer’s Disease
Biogen got the go-ahead under the FDA’s accelerated approval pathway, which requires change in a surrogate biomarker and Phase 4 studies to verify a clinical benefit.
Dale Schenk, 59, Pioneer of Alzheimer’s Immunotherapy
Schenk loses two-year battle with pancreatic cancer.
Finally: Big Win on All Outcomes for Lecanemab in Phase 3 Topline Results
Drug sponsors Eisai and Biogen said they will apply for approval in Europe, the U.S., and Japan; more detailed data will be presented at CTAD.
No Easy Answers on Clinical Meaningfulness of Alzheimer’s Treatments
Meaningfulness must account for the disease stage a patient is at, his or her priorities, and effects over time, researchers say.
Field Loses Beloved Wizard of Glia, Ben Barres, 63
Pancreatic cancer felled the man who led groundbreaking research on astrocytes, oligodendrocytes, and microglia.
Field Loses GSM Developer Steven Wagner, 64
Wagner pioneered γ-secretase modulators to treat Alzheimer’s disease, with a candidate slated to enter Phase 1 trials later this year.
Mark Smith, 45, Is Struck and Killed by Hit-and-Run Driver
As shocked researchers notify each other privately, the Alzforum editors are saddened to inform the community at large that Mark Smith died last Sunday...
And Then There Were Three: Donanemab Phase 3 Trial Positive
The antibody slowed decline by 35 percent, met secondary endpoints, will likely be approved. Major question: How to avoid severe ARIA.
Neuropathologist Charles Duyckaerts Passes Away at Age 70
Stalwart of dementia neuropathology was best known for his work on tau pathology.
Biogen/Eisai Halt Phase 3 Aducanumab Trials
Futility analysis predicts failure to reach primary endpoint.
Drilling Down into the CMS Aduhelm Decision—A Primer
In its national coverage determination, Medicare limits Aduhelm coverage to clinical trials, but OKs registry-based studies for traditionally approved anti-Aβ antibodies. This may change once new efficacy data comes out.
Current Filters
No filters selected